57 results about "Virus host" patented technology

The present invention is directed to genetically engineered, membrane-enveloped viruses with deletion mutations in the protein transmembrane domains. Also provided are viral vaccines based on the engineered viruses, methods of producing and using such vaccines.

The invention concerns an Avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene. The invention further relates to cells, preferably avian cells, comprising a Vaccinia virus host range gene or a homologue of said host range gene. Moreover the invention concerns the use of a Vaccinia virus host range gene or an homologue thereof to increase the titer of avipoxviruses produced from cells after infection of said cells with the avipoxvirus, wherein the host range gene is expressed in said cells.

The invention discloses a sialyloligosaccharide-gold nano particle and a preparation method and applications thereof. The sialyloligosaccharide-gold nano particle which is used for detecting influenza virus host specificity is a gold nano particle which connects sialic acid Alpha 2, 3 or Alpha 2, 6 oligose-O(CH2CH2O)m(CO)n(CH2)k(CH)pSR and HO(CH2CH2O)m(CO)n(CH2)k(CH)pSR through an S-Au key on the surface. When the sialyloligosaccharide-gold nano particle is used for detecting influenza virus strain or HA (Hemagglutinin) protein, receptor specificity of a to-be-detected influenza virus is rapidly obtained through naked eye observation, sensitivity of detecting the influenza virus HA protein can achieve 2.5 nm. The preparation method of the sialyloligosaccharide-gold nano particle enables interaction information between the influenza virus and host cells to be conveniently and rapidly obtained and has significance to influenza virus prevention and control.

The invention provides a dry powder composition for a zooblast culture medium. Compared with the prior dry powder composition for the zooblast culture medium, the dry powder composition provided by the invention reduces the serum dosage of animals by introduction of recombinant protein or animal origin compositions, the dry powder composition for the zooblast culture medium can be matched with low-content animal serum for use without additional introduction of protein compositions (such as the recombinant protein, plant protein or the animal origin compositions including cytokines and so on),and has the same or better function on promoting the growth of zooblast compared with high-content animal serum, so that the dry powder composition for the zooblast culture medium does not generate side effects along with the protein compositions, and has good safety and low cost. Cells cultured by the dry powder composition for the zooblast culture medium have small difference for different batches, low cost and good safety, are favorable for separating downstream products of the cells, and are suitable to be used for virus hosts, expression vectors and so on of biological products and otherbiological products.

Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.

Described are single-stranded new sequences of TT viruses, rearranged TTV sequences and hybrid molecules of a specific TT virus sequence and host cell DNA that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. In addition, it relates to the use of such molecules as gene vectors and artificial chromosomes.

The invention discloses an anti-virus host product-oriented test system. The system includes a test management module and a test execution module. The test management module includes a management and control unit, a test case library, a virus sample library, an analysis and judgment unit and a test report unit, and is used for managing test processes, test cases and virus samples, analyzing and judging test results and generating test reports. The test execution module includes a C&C server (command and control server), sandboxes, a virus monitoring server and an environment restoration unit, and is used for executing test tasks and returning test data. The invention also discloses an anti-virus host product-oriented test method at the same time. Through the system and the method, problems of low efficiency, insufficient accuracy, nonstandard processes, incomplete test contents and the like which are ubiquitous in current tests can be solved, and the test capability and efficiency are greatly improved.

The present invention provides a method for tertiary purification of virus particles from a sample containing host cells packaging virus particles. The three-stage purification method includes: using the first fractionation solution to precipitate and remove most of the impurity proteins; using the second fractionation solution to precipitate and collect virus particles to remove some remaining impurities; the collected virus particles are further purified by column layer The remaining impurities were removed by analysis to obtain an ultra-pure virus solution. The method also includes the steps of collecting virus host cells, cell suspending and cell lysing. This purification method is easy to operate, convenient to obtain ultra-pure virus solution with high recovery rate, suitable for large-scale and small-scale preparation, and the solution and operation steps used do not contain toxic substances to cells. Therefore, this method represents a highly desirable purification technique for vector viruses, including AAVs and adenoviruses. The present invention also includes kits or packages designed according to the above techniques.